Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 6:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 62 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Lexicon Pharmaceuticals Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy

NCT03332771
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954), Glimepiride, Metformin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
954 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
115
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 101 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 5, 2026, 6:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects

NCT01818232
View directory record Official record
Conditions
Healthy
Interventions
[14C]-LX4211
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Oct 5, 2026, 6:05 PM EDT
Completed Phase 2 Interventional

A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)

NCT06203002
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Placebo (blinded), LX9211 (blinded)
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
108
States / cities
Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 5, 2026, 6:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects

NCT02147808
View directory record Official record
Conditions
Drug Interactions
Interventions
Telotristat etiprate, Midazolam
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 5, 2026, 6:05 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure

NCT03292653
View directory record Official record
Conditions
Cardiac Failure Aggravated
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
La Jolla, California • New Haven, Connecticut • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 5, 2026, 6:05 PM EDT
Completed Phase 1Phase 2 Interventional

Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

NCT01528111
View directory record Official record
Conditions
Primary Open-angle Glaucoma, Ocular Hypertension
Interventions
LX7101 (0.125%), LX7101 (0.25%), LX7101 Vehicle
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
5
States / cities
Morrow, Georgia • Memphis, Tennessee • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2015 · Synced Oct 5, 2026, 6:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects

NCT01411800
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
250 mg capsule, 250 mg tablets
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 5, 2026, 6:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DDI Study With Multiple-dose LX4211 and Single Dose Digoxin

NCT02300350
View directory record Official record
Conditions
Healthy
Interventions
Treatment A digoxin, Treatment B LX4211, Treatment C Digoxin + 400 mg LX4211 administered concomitantly
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 5, 2026, 6:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy

NCT02926937
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954), Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
56
States / cities
Tucson, Arizona • Anaheim, California • Canoga Park, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 5, 2026, 6:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets

NCT02373046
View directory record Official record
Conditions
Healthy
Interventions
LX4211
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 5, 2026, 6:05 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs

NCT06933056
View directory record Official record
Conditions
Platelet Function and Reactivity Tests
Interventions
Sotagliflozin (SOTA) followed by 3 drugs in a random order, Aspirin followed by 3 drugs in a random order, Clopidogrel followed by 3 drugs in a random order, Eliquis followed by 3 drugs in a random order
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 79 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 5, 2026, 6:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy

NCT02384941
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Placebo, Sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
63
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 5, 2026, 6:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label Food Effect Study of Telotristat Etiprate

NCT02157584
View directory record Official record
Conditions
Healthy
Interventions
Telotristat etiprate
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 5, 2026, 6:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects

NCT02195635
View directory record Official record
Conditions
Drug Interactions
Interventions
Telotristat etiprate, Octreotide acetate
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2016 · Synced Oct 5, 2026, 6:05 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus

NCT01742208
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Baton Rouge, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 5, 2026, 6:05 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C

NCT02383940
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 30 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Tustin, California • Aurora, Colorado • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 5, 2026, 6:05 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain

NCT04455633
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy, Diabetes
Interventions
LX9211, LX9211 Matching Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
44
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 5, 2026, 6:05 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Oral Contraceptive DDI Study

NCT02494609
View directory record Official record
Conditions
Healthy
Interventions
sotagliflozin, oral contraceptive, oral contraceptive + sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
2
States / cities
Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 5, 2026, 6:05 PM EDT
Completed Phase 1 Interventional

A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

NCT01417052
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
50 mg LX3305 QD, 100 mg LX3305 QD, 150 mg LX3305 QD, 200 mg LX3305 QD, 250 mg LX3305 QD, 300 mg LX3305 QD, 400 mg LX3305 QD, 250 mg LX3305 BID, 500 mg LX3305 QD, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 5, 2026, 6:05 PM EDT
Completed Phase 1 Interventional Results available

Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis

NCT00847886
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LX3305, LX3305 Placebo, Methotrexate
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2010 · Synced Oct 5, 2026, 6:05 PM EDT
Recruiting Phase 3 Interventional

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

NCT06217302
View directory record Official record
Conditions
Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Alessandro Doria
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
13
States / cities
Stanford, California • Aurora, Colorado • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 5, 2026, 6:05 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

NCT03386344
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
Escondido, California • Greenbrae, California • Walnut Creek, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 5, 2026, 6:05 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes

NCT05696366
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Sotagliflozin, Volagidemab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 5, 2026, 6:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin

NCT03351478
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin, Empagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
53
States / cities
Birmingham, Alabama • Sheffield, Alabama • Hawaiian Gardens, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 5, 2026, 6:05 PM EDT